PHAT - NASDAQ
Phathom Pharmaceuticals, Inc.
$10.09
+4.6%Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
At a Glance
Live SnapshotPhathom Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Phathom Pharmaceuticals, Inc. Income Statement
PHAT • NASDAQ
| Phathom Pharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
175.1M | 55.3M | 682K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||
(22.6M) | (8M) | (167K) | (620K) | (521K) | (300K) | (8K) | (0.0) | |
152.5M | 47.3M | 515K | -620K | -521K | -300K | -8K | 0.0 | |
OPERATING INCOME | ||||||||
(312.5M) | (324.7M) | (167.8M) | (171.8M) | (134.6M) | (125.4M) | (106.2M) | (1.2M) | |
(279.7M) | (290.7M) | (117.9M) | (100.4M) | (62.2M) | (27.2M) | (6.9M) | (1.2M) | |
(32.8M) | (34.1M) | (49.9M) | (71.4M) | (72.3M) | (98.1M) | (99.3M) | (20K) | |
-160M | -277.5M | -167.3M | -172.4M | -135.1M | -125.7M | -106.2M | -1.2M | |
PRE-TAX INCOME | ||||||||
(68.1M) | (72M) | (42M) | (27.3M) | (6.8M) | (4.6M) | (4.2M) | (13K) | |
-61.1M | -56.9M | -34.1M | -25.2M | -6.7M | -3.5M | -3.1M | 0.0 | |
-61.3M | -56.9M | -34.3M | -25.3M | -8.8M | -3.4M | -148.9M | -63K | |
-221.2M | -334.3M | -201.6M | -197.7M | -143.9M | -129.1M | -255.1M | -1.3M | |
NET INCOME | ||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (13K) | |
-221.2M | -334.3M | -201.6M | -197.7M | -143.9M | -129.1M | -209.7M | -1.3M |
SEC Filings
PHAT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | May 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 |
Related Guides
Continue your PHAT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.